Skip to main content
Premium Trial:

Request an Annual Quote

Susan Desmond-Hellmann, Thomas Heydler, Andras Guttman, Paul Lucas, Neil M. Reid, Michael Mueller, R.H. Joseph Shaw


Susan Desmond-Hellmann has been named to the board of directors of Affymetrix, the company said this week. Desmond-Hellman oversees regulatory affairs, medical affairs, product development, and other functions for Genentech. She also serves on the Biotechnology Industry Organization’s board of directors’ executive committee. In connection with the appointment, Desmond-Hellman received options to purchase 20,000 Affymetrix shares at a price of $32.62. The options are exercisable and expire on Nov. 17, 2014.

Definiens has appointed Thomas Heydler as its new CEO. Prior to joining Definiens, Thomas was president and CEO at InterPro Business Solutions and Barcelona Design. He also served as vice president at Documentum, and held senior management positions at Cadence Design Systems and Siemens.

Andras Guttman has joined the scientific advisory board of Irvine, Calif.-based eGene, the company said recently. Guttman leads the Horvath Laboratory of Bioseparation Sciences at the University of Innsbruck, Austria. The institute pursues research in bioseparation for application in genomics, proteomics, and metabolomics. Guttman previously held appointments at Diversa, Torrey Mesa Research Institute, Genetic BioSystems, and at Beckman Coulter.

TM Bioscience has appointed Paul Lucas chairman of the company’s board of directors. Lucas is currently president and CEO of GlaxoSmithKline Canada and has served as an independent director of TM since 2002. The Toronto-based firm also announced that Neil M. Reid was appointed vice chairman and Michael Mueller was appointed to the board of directors. Reid has served as a director of TM since 2000 and is currently senior vice president of Protana. Mueller currently serves as president and CEO of MDS Capital.

R.H. Joseph Shaw has been named CEO and a member of the board of directors of OpGen, a Madison, Wis.-based firm developing single-molecule DNA analysis technology. Shaw previously served as president of Bank On A Cure, a project of the International Myeloma Foundation. Before that, he served as president and CEO of Ambri Limited, and CEO and chairman of Quantech.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.